Rani Therapeutics surges on Chugai licensing deal, private placement
Source: SeekingAlpha
2025-10-17 09:56:27 ET
More on Rani Therapeutics, Chugai Pharmaceutical Co., Ltd.
- Chugai Pharmaceutical Co., Ltd. 2025 Q2 - Results - Earnings Call Presentation
- Chugai Pharmaceutical Co., Ltd. (CHGCF) Q2 2025 Earnings Call Transcript
- Rani Therapeutics secures $60.3M in private placement to fund pipeline through 2028
- Trump’s 100% drug tariffs send pharma stocks lower
- Seeking Alpha’s Quant Rating on Rani Therapeutics
Read the full article on Seeking Alpha
For further details see:
Rani Therapeutics surges on Chugai licensing deal, private placement
Rani Therapeutics Holdings Inc.
NASDAQ: RANI
RANI Trading
1.16% G/L:
$1.31 Last:
286,763 Volume:
$1.30 Open:
RANI Latest News
January 28, 2026 07:00:00 am
Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer
January 08, 2026 07:00:00 am
Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen
November 24, 2025 04:05:00 pm
Rani Therapeutics to Participate in the Evercore Healthcare Conference
November 06, 2025 04:30:00 pm
Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update
RANI Stock Data
$162,838,596
86,413,825
3.84%
30
N/A
Biotechnology & Life Sciences
Healthcare
US
San Jose
